Molecular and Clinical Responses in a Pilot Study of Gefitinib With Paclitaxel and Radiation in Locally Advanced Head-and-Neck Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 77, Issue 2, 2010, Pages 447-454

  Van Waes, Carter ^a,b   Allen, Clint T ^a   Citrin, Deborah ^b   Gius, David ^b   Colevas, A Dimetrios ^b   Harold, Nancy A ^b   Rudy, Susan ^a   Nottingham, Liesl ^a   Muir, Christine ^b   Chen, Zhong ^a   Singh, Anurag K ^b   Dancey, Janet ^b   Morris, John C ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Epidermal growth factor receptor; Gefitinib; Head and neck cancer; Paclitaxel; Radiation

Indexed keywords

APOPTOSIS; BIOPSY SAMPLES; CELLULAR PROLIFERATIONS; CLINICAL RESPONSE; COMPLETE RESPONSE; DOSE-ESCALATION STUDY; EGFR SIGNALING; EPIDERMAL GROWTH FACTOR RECEPTORS; GEFITINIB; HEAD-AND-NECK CANCER; HEAD-AND-NECK SQUAMOUS CELL CARCINOMA; INTERSTITIAL PNEUMONINITIDES; MAXIMUM TOLERATED DOSE; ORGAN FUNCTIONS; OVER-EXPRESSION; PACLITAXEL; PARTIAL RESPONSE; PILOT PHASE; PILOT STUDIES; PRIOR EXPERIENCE; RADIATION RESISTANCE; RADIATION THERAPY; TREATMENT EFFECTS; TUMOR CELLS;

BIOACTIVITY; BIOPSY; CELL DEATH; CELL PROLIFERATION; CHEMOTHERAPY; GROWTH KINETICS; PEPTIDES; PHOSPHORYLATION; RADIATION EFFECTS; SIGNALING; TOXICITY; TUMORS;

RADIOTHERAPY;

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; ASPIRATION PNEUMONIA; BONE NECROSIS; CANCER INHIBITION; CANCER RADIOTHERAPY; CELLULITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYSPHAGIA; DYSPHONIA; DYSPNEA; EDEMA; EPISTAXIS; ESOPHAGITIS; FATIGUE; FEMALE; FLUSHING; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEART ARRHYTHMIA; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOTENSION; HYPOXIA; INFECTION; INJECTION SITE REACTION; INTERSTITIAL PNEUMONIA; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; NAUSEA; ORAL DYSESTHESIA; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PRURITUS; RADIATION DERMATITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; STOMATITIS; THROMBOCYTOPENIA; TINNITUS; TREATMENT RESPONSE; TRISMUS; TUMOR BIOPSY; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INFECTION; LUNG DISEASES, INTERSTITIAL; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM PROTEINS; PACLITAXEL; PILOT PROJECTS; QUINAZOLINES; RADIOTHERAPY DOSAGE; RECEPTOR, EPIDERMAL GROWTH FACTOR; REMISSION INDUCTION; STOMATITIS;

EID: 77951782182     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.05.037     Document Type: Article

References (37)

1. Kim S., Grandis J.R., Rinaldo A., et al. Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer. Head Neck 30 (2008) 667-674
2. Yarden Y. The EGFR family and its ligands in human cancer. Signaling mechanisms and therapeutic opportunities. Eur J Cancer 37 Suppl 4 (2001) S3-S8
3. Bancroft C.C., Chen Z., Yeh J., et al. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 99 (2002) 538-548
4. Grandis J.R., Drenning S.D., Zeng Q., et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A 97 (2000) 4227-4232
5. Lee T.L., Yeh J., Van Waes C., and Chen Z. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas. Mol Cancer Ther 5 (2006) 8-19
6. Lee T.L., Yeh J., Friedman J., et al. A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas. Int J Cancer 122 (2008) 1987-1998
7. Rubin Grandis J., Melhem M.F., Gooding W.E., et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90 (1998) 824-832
8. Ang K.K., Berkey B.A., Tu X., et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62 (2002) 7350-7356
9. Dickstein B.N., Wosikowski K., and Bates S. Increased resistance to cytotoxic agents in ZR75B human breast cancer cells transfected with epidermal growth factor receptor. Mol Cell Endocrinol 110 (1995) 205-211
10. Wosikowski K., Schuurhuis D., Kops G.J., et al. Altered gene expression in drug-resistant human breast cancer cells. Clin Cancer Res 2 (1997) 2405-2414
11. Akimoto T., Hunter N.R., Buchmiller L., et al. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 5 (1999) 2884-2890
12. Ling Y.H., Donato N.J., and Perez-Soler R. Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines. Cancer Chemother Pharmacol 47 (2001) 473-480
13. Wieduwilt M.J., and Moasser M.M. The epidermal growth factor receptor family: Biology driving targeted therapeutics. Cell Mol Life Sci 65 (2008) 1566-1584
14. Milas L., Mason K., Hunter N., et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6 (2000) 701-708
15. Huang S.M., Li J., Armstrong E.A., and Harari P.M. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 62 (2002) 4300-4306
16. Bianco R., Caputo R., Veneziani B.M., et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 8 (2002) 3250-3258
17. Sirotnak F.M., Zakowski M.F., Miller V.A., et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6 (2000) 4885-4892
18. Cohen E.E., Rosen F., Stadler W.M., et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21 (2003) 1980-1987
19. Chen C., Kane M., Song J., et al. Phase I trail of gefitinib in combination with radiation or chemoradiation for patients with locally advanced head and neck cancer. J Clin Oncol 25 (2007) 4880-4886
20. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
21. Paez J.G., Jänne P.A., Lee J.C., et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
22. Lee J.W., Soung Y.H., Kim S.Y., et al. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 11 (2005) 2879-2882
23. Squarize C.H., Castilho R.M., Sriuranpong V., et al. Molecular cross-talk between the NFkappaB and STAT3 signaling pathways in head and neck squamous cell carcinoma. Neoplasia 8 (2006) 733-746
24. Al-Sarraf M., Pajak T.F., Byhardt R.W., et al. Postoperative radiotherapy with concurrent cisplatin appears to improve locoregional control of advanced, resectable head and neck cancers: RTOG 88-24. Int J Radiat Oncol Biol Phys 37 (1997) 777-782
25. Nabell L., and Spencer S. Docetaxel with concurrent radiotherapy in head and neck cancer. Semin Oncol 30 6 Suppl. 18 (2003) 89-93
26. Sunwoo J.B., Herscher L.L., Kroog G.S., et al. Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer. J Clin Oncol 19 (2001) 800-811
27. Specenier P., and Vermorken J.B. The role of taxanes and targeted therapies in locally advanced head and neck cancer. Curr Opin Oncol 19 (2007) 195-201
28. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
29. Cox J.D., Stetz J., and Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (1995) 1341-1346
30. Nenutil R., Smardova J., Pavlova S., et al. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol 207 (2005) 251-259
31. Sharp H., Morris J.C., Van Waes C., et al. High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. Am J Clin Oncol 31 (2008) 557-560
32. Bancroft C.C., Chen Z., Dong G., et al. Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways. Clin Cancer Res 7 (2001) 435-442
33. Wolf J.S., Chen Z., Dong G., et al. IL (interleukin)-1alpha promotes nuclear factor-kappaB and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas. Clin Cancer Res 7 (2001) 1812-1820
34. Van Waes C. Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 13 (2007) 1076-1082
35. Wang J., Seethala R.R., Zhang Q., et al. Autocrine and paracrine chemokine receptor 7 activation in head and neck cancer: Implications for therapy. J Natl Cancer Inst 100 (2008) 502-512
36. Hong S.H., Ondrey F.G., Avis I.M., et al. Cyclooxygenase regulates human oropharyngeal carcinomas via the proinflammatory cytokine IL-6: A general role for inflammation?. FASEB J 14 (2000) 1499-1507
37. Pernas F.G., Allen C.T., Winters M.E., et al. Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer. Clin Cancer Res 15 (2009) 2361-2372